View ValuationDermapharm Holding 향후 성장Future 기준 점검 1/6Dermapharm Holding (는) 각각 연간 6.9% 및 3.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.1% 로 예상됩니다.핵심 정보6.9%이익 성장률7.46%EPS 성장률Pharmaceuticals 이익 성장9.9%매출 성장률3.7%향후 자기자본이익률18.12%애널리스트 커버리지Good마지막 업데이트03 Jun 2026최근 향후 성장 업데이트공고 • Jun 28Dermapharm Holding Se Confirms Earnings Guidance for 2026Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million.모든 업데이트 보기Recent updates공고 • Jun 28Dermapharm Holding Se Confirms Earnings Guidance for 2026Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million.공고 • May 19Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time.공고 • Apr 01Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.공고 • Mar 11Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million.Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026.공고 • Nov 19+ 1 more updateDermapharm Holding SE to Report First Half, 2026 Results on Aug 11, 2026Dermapharm Holding SE announced that they will report first half, 2026 results on Aug 11, 2026공고 • Nov 13+ 3 more updatesDermapharm Holding SE to Report Fiscal Year 2025 Results on Mar 31, 2026Dermapharm Holding SE announced that they will report fiscal year 2025 results on Mar 31, 2026공고 • Jun 28Dermapharm Holding SE Approves Annual DividendDermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution.공고 • May 16Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time.공고 • Jan 02Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025공고 • May 09Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024Dermapharm Holding SE announced that they will report Q1, 2024 results on May 15, 2024공고 • Mar 28Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024.공고 • Mar 14Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024Dermapharm Holding SE announced that they will report fiscal year 2023 results on Mar 28, 2024Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €45.46, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €73.48 per share.Reported Earnings • Mar 31Full year 2022 earnings released: EPS: €2.49 (vs €3.89 in FY 2021)Full year 2022 results: EPS: €2.49 (down from €3.89 in FY 2021). Revenue: €1.04b (up 8.4% from FY 2021). Net income: €134.2m (down 36% from FY 2021). Profit margin: 13% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €36.74, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 14x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 2.6% over the past three years.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to €44.92, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 27% over the past three years.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)Third quarter 2022 results: EPS: €0.98 (down from €1.15 in 3Q 2021). Revenue: €277.8m (up 13% from 3Q 2021). Net income: €52.5m (down 15% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 17Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to €37.52, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years.Reported Earnings • Sep 09Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)Second quarter 2022 results: EPS: €0.27 (down from €0.74 in 2Q 2021). Revenue: €246.2m (up 12% from 2Q 2021). Net income: €14.5m (down 64% from 2Q 2021). Profit margin: 5.9% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 6.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 26Upcoming dividend of €2.17 per shareEligible shareholders must have bought the stock before 02 June 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 4.6%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%).Reported Earnings • May 19First quarter 2022 earnings released: EPS: €0.69 (vs €0.67 in 1Q 2021)First quarter 2022 results: EPS: €0.69 (up from €0.67 in 1Q 2021). Revenue: €239.1m (up 11% from 1Q 2021). Net income: €37.4m (up 2.9% from 1Q 2021). Profit margin: 16% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.8%, compared to a 5.3% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 14Full year 2021 earnings released: EPS: €3.89 (vs €1.59 in FY 2020)Full year 2021 results: EPS: €3.89 (up from €1.59 in FY 2020). Revenue: €960.1m (up 19% from FY 2020). Net income: €209.6m (up 144% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 10%, compared to a 13% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €264.5m (up 31% from 3Q 2020). Net income: €61.8m (up 173% from 3Q 2020). Profit margin: 23% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Sep 08Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €219.1m (up 16% from 2Q 2020). Net income: €39.8m (up 233% from 2Q 2020). Profit margin: 18% (up from 6.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jun 17Upcoming dividend of €0.88 per shareEligible shareholders must have bought the stock before 24 June 2021. Payment date: 28 June 2021. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (4.0%). Lower than average of industry peers (3.6%).Reported Earnings • May 21First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €218.0m (up 11% from 1Q 2020). Net income: €36.3m (up 36% from 1Q 2020). Profit margin: 17% (up from 14% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improved over the past weekAfter last week's 21% share price gain to €74.65, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 24x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 89% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.84 per share.Reported Earnings • Apr 16Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €820.5m (up 15% from FY 2019). Net income: €85.8m (up 11% from FY 2019). Profit margin: 11% (in line with FY 2019).Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to €64.69, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 83% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.89 per share.Is New 90 Day High Low • Feb 05New 90-day high: €60.89The company is up 32% from its price of €46.10 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.45 per share.Is New 90 Day High Low • Dec 29New 90-day high: €57.29The company is up 26% from its price of €45.54 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.08 per share.Is New 90 Day High Low • Dec 01New 90-day high: €55.96The company is up 22% from its price of €45.82 on 02 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.89 per share.이익 및 매출 성장 예측BATS-CHIXE:DMPD - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,299171186254512/31/20271,254155177241612/31/20261,20913917824163/31/20261,182144241285N/A12/31/20251,178132187229N/A9/30/20251,174116164207N/A6/30/20251,191107175216N/A3/31/20251,199104131173N/A12/31/20241,195114163201N/A9/30/20241,17491157197N/A6/30/20241,14783146187N/A3/31/20241,12957137179N/A12/31/20231,15162178219N/A9/30/20231,17295240279N/A6/30/20231,151123267304N/A3/31/20231,128146287323N/A12/31/20221,041134250289N/A9/30/20221,024176222269N/A6/30/20221,004185191249N/A3/31/2022980211190252N/A12/31/2021960210189250N/A9/30/2021902162153209N/A6/30/2021858123115164N/A3/31/20218289596139N/A12/31/20208088690131N/A9/30/20207758060104N/A6/30/2020760775897N/A3/31/20207438569114N/A12/31/201971477N/A101N/A9/30/201967473N/A90N/A6/30/201963977N/A109N/A3/31/201961173N/A115N/A12/31/201858475N/A159N/A9/30/201855875N/A165N/A6/30/201852576N/A137N/A3/31/201849879N/A120N/A12/31/201748078N/A87N/A9/30/201748684N/A84N/A12/31/201645577N/A77N/A12/31/201539613N/A40N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: DMPD 의 연간 예상 수익 증가율(6.9%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: DMPD 의 연간 수익(6.9%)이 UK 시장(11.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: DMPD 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: DMPD 의 수익(연간 3.7%)이 UK 시장(연간 4.6%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: DMPD 의 수익(연간 3.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: DMPD의 자본 수익률은 3년 후 18.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/13 18:44종가2026/04/23 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Dermapharm Holding SE는 12명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gerhard OrgonasBerenbergFabian PiastaJefferies LLCMartin ComtesseJefferies LLC9명의 분석가 더 보기
공고 • Jun 28Dermapharm Holding Se Confirms Earnings Guidance for 2026Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million.
공고 • Jun 28Dermapharm Holding Se Confirms Earnings Guidance for 2026Dermapharm Holding SE confirmed earnings guidance for 2026. The company expects consolidated revenue of between EUR 1,182 million and EUR 1,218 million.
공고 • May 19Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time.
공고 • Apr 01Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.
공고 • Mar 11Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million.Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026.
공고 • Nov 19+ 1 more updateDermapharm Holding SE to Report First Half, 2026 Results on Aug 11, 2026Dermapharm Holding SE announced that they will report first half, 2026 results on Aug 11, 2026
공고 • Nov 13+ 3 more updatesDermapharm Holding SE to Report Fiscal Year 2025 Results on Mar 31, 2026Dermapharm Holding SE announced that they will report fiscal year 2025 results on Mar 31, 2026
공고 • Jun 28Dermapharm Holding SE Approves Annual DividendDermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution.
공고 • May 16Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time.
공고 • Jan 02Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025
공고 • May 09Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024Dermapharm Holding SE announced that they will report Q1, 2024 results on May 15, 2024
공고 • Mar 28Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024.
공고 • Mar 14Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024Dermapharm Holding SE announced that they will report fiscal year 2023 results on Mar 28, 2024
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €45.46, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €73.48 per share.
Reported Earnings • Mar 31Full year 2022 earnings released: EPS: €2.49 (vs €3.89 in FY 2021)Full year 2022 results: EPS: €2.49 (down from €3.89 in FY 2021). Revenue: €1.04b (up 8.4% from FY 2021). Net income: €134.2m (down 36% from FY 2021). Profit margin: 13% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €36.74, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 14x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 2.6% over the past three years.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 18% share price gain to €44.92, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 27% over the past three years.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)Third quarter 2022 results: EPS: €0.98 (down from €1.15 in 3Q 2021). Revenue: €277.8m (up 13% from 3Q 2021). Net income: €52.5m (down 15% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 17Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to €37.52, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 21% over the past three years.
Reported Earnings • Sep 09Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)Second quarter 2022 results: EPS: €0.27 (down from €0.74 in 2Q 2021). Revenue: €246.2m (up 12% from 2Q 2021). Net income: €14.5m (down 64% from 2Q 2021). Profit margin: 5.9% (down from 18% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 6.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 26Upcoming dividend of €2.17 per shareEligible shareholders must have bought the stock before 02 June 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 4.6%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%).
Reported Earnings • May 19First quarter 2022 earnings released: EPS: €0.69 (vs €0.67 in 1Q 2021)First quarter 2022 results: EPS: €0.69 (up from €0.67 in 1Q 2021). Revenue: €239.1m (up 11% from 1Q 2021). Net income: €37.4m (up 2.9% from 1Q 2021). Profit margin: 16% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.8%, compared to a 5.3% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 14Full year 2021 earnings released: EPS: €3.89 (vs €1.59 in FY 2020)Full year 2021 results: EPS: €3.89 (up from €1.59 in FY 2020). Revenue: €960.1m (up 19% from FY 2020). Net income: €209.6m (up 144% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 10%, compared to a 13% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €264.5m (up 31% from 3Q 2020). Net income: €61.8m (up 173% from 3Q 2020). Profit margin: 23% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Sep 08Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €219.1m (up 16% from 2Q 2020). Net income: €39.8m (up 233% from 2Q 2020). Profit margin: 18% (up from 6.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jun 17Upcoming dividend of €0.88 per shareEligible shareholders must have bought the stock before 24 June 2021. Payment date: 28 June 2021. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (4.0%). Lower than average of industry peers (3.6%).
Reported Earnings • May 21First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €218.0m (up 11% from 1Q 2020). Net income: €36.3m (up 36% from 1Q 2020). Profit margin: 17% (up from 14% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improved over the past weekAfter last week's 21% share price gain to €74.65, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 24x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 89% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.84 per share.
Reported Earnings • Apr 16Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €820.5m (up 15% from FY 2019). Net income: €85.8m (up 11% from FY 2019). Profit margin: 11% (in line with FY 2019).
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improved over the past weekAfter last week's 16% share price gain to €64.69, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 25x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 83% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €81.89 per share.
Is New 90 Day High Low • Feb 05New 90-day high: €60.89The company is up 32% from its price of €46.10 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.45 per share.
Is New 90 Day High Low • Dec 29New 90-day high: €57.29The company is up 26% from its price of €45.54 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.08 per share.
Is New 90 Day High Low • Dec 01New 90-day high: €55.96The company is up 22% from its price of €45.82 on 02 September 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.89 per share.